Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure - 21/08/11
, Shuki Patal, MD, Dov Wexler, MD, Arie Roth, MD, David Sheps, MD, Gad Keren, MDRiassunto |
Background |
Extracellular matrix remodeling is thought to play an important role in the progression of heart failure (HF). Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are matrix-degrading enzymes that have been demonstrated to influence left ventricular properties and serve as targets of potential anti-remodeling agents. Herein we evaluated the potential significance of circulating MMP and TIMP levels in patients with congestive HF (CHF) speculating it may assume prognostic value.
Methods |
Serum samples were obtained from 88 consecutive patients attending the outpatient HF clinic and analyzed for MMP-2, -3, -9, and TIMP-1 as well as N-terminal probrain natriuretic peptide (NT-ProBNP). Patients were followed up for the occurrence of either mortality or hospitalizations due to CHF or either of each.
Results |
Circulating levels of MMP-2, -9, and TIMP-1 but not of MMP-3 were increased in patients with CHF as compared with age-matched controls. Only MMP-2 and NT-ProBNP levels correlated significantly with New York Heart Association class. Matrix metalloproteinase-2 and NT-ProBNP levels did not correlate. Patients with circulating MMP-2 above 352 ng/mL were 4.2 times more likely to die, 2.2 times more likely to be hospitalized because of CHF, and 2.3 times more likely to experience either of the 2 end points as compared with patients with MMP-2 concentrations below this threshold.
Both MMP-2 and NT-ProBNP were found to be independent predictors of mortality over a 24-month follow-up period.
Conclusions |
Matrix metalloproteinase-2 but not MMP-3, -9, or TIMP-1 serum levels is an independent predictor of mortality in patients with CHF.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 150 - N° 3
P. 484-487 - settembre 2005 Ritorno al numero
Articolo precedente
- A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy
- Philip J. Gentlesk, Thomas Wiley, Allen J. Taylor
- Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: Further evidence for the inflammatory basis of atherosclerosis
- Gemma Satterthwaite, Sheila E. Francis, Kim Suvarna, Stephen Blakemore, Chantelle Ward, Don Wallace, Martin Braddock, David Crossman
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?